About 490 results
Natpar(a): A Case in Point for Rare Disease Drugs?

Dec 17th, 2019 - While the recent recall of injectable recombinant parathyroid hormone (PTH) (Natpara, Takeda) in the United States has grabbed the headlines, the situation for patients with chronic hypoparathyroidism who want to take the drug in Europe (where it's known as Natpar), and the rest of North America, is hardly any better. Although the drug has not gone through the ignominy of being made available a...

Drug Recall in US Causes Hypoparathyroid Patients Extreme Hardship

Dec 1st, 2019 - The recall of injectable recombinant parathyroid hormone (PTH) (Natpara, Takeda) in the United States over safety concerns about the product is gravely affecting the lives of American patients with severe hypoparathyroidism who need replacement PTH therapy to adequately control symptoms. Approximately 2700 patients in the United States have been affected by the recall of Natpara, according to T...

PET/CT May Be Useful for Challenging Cases of Hyperparathyroidism

Jun 10th, 2019 - NEW YORK (Reuters Health) - For patients with hyperparathyroidism, 18F-fluorocholine positron emission tomography - computed tomography (PET/CT) may be indicated in difficult cases and when first-line tests are negative or discordant, researchers suggest. "Identifying parathyroid glands correctly before a surgical procedure is essential to perform minimally invasive surgery," note Dr. Luis Alej...

Discovery Could Herald 'Game Changer' for Hyperparathyroidism

Jun 6th, 2019 - A study in animals suggests hope may be on the horizon for a novel agent to treat hyperparathyroidism. Mice that were deficient in semaphorin3d (Sema3d), a secreted protein, developed an abnormally large parathyroid gland, but inhibiting a signaling pathway involved in this process partially "rescued" them, in a new study. The finding suggests that an effective, safe recombinant protein drug th...

Parathyroid Hormone Replacement Effective, Safe Long Term

Apr 3rd, 2019 - NEW ORLEANS — Recombinant human parathyroid hormone 1-84 (rhPTH[1-84]) (Natpara, Shire) was safe and effective over 6 years of continuous use for the treatment of adults with chronic hypoparathyroidism, new research shows. Findings from the long-term, open-label RACE extension study were presented March 26 here at ENDO 2019: The Endocrine Society Annual Meeting by John P. Bilezikian, MD, profes...

DDSEP® 8 Quick Quiz Question 2

Mar 29th, 2019 - Critique: Factors raising suspicion for Zollinger-Ellison syndrome include recurrent peptic ulcer disease, multiple ulcers, post-bulbar ulcer, non-H. pylori/non-NSAID-related duodenal ulcer, diarrhea, erosive esophagitis, and family or personal history of multiple endocrine neoplasia type 1.

April 2019 - Question 2

Mar 29th, 2019 - Critique: Factors raising suspicion for Zollinger-Ellison syndrome include recurrent peptic ulcer disease, multiple ulcers, post-bulbar ulcer, non-H. pylori/non-NSAID-related duodenal ulcer, diarrhea, erosive esophagitis, and family or personal history of multiple endocrine neoplasia type 1.

Active Vitamin D No Help for CV Events in Select CKD Patients

Dec 19th, 2018 - Action Points Among patients without secondary hyperparathyroidism undergoing maintenance hemodialysis, oral alfacalcidol compared with usual care did notreduce the risk of a composite measure of select cardiovascular events. The researchers cautioned against the use of vitamin D receptor activators for patients with end-stage kidney disease without secondary hyperparathyroidism receiving maint...

Alfacalcidol Does Not Lower CV Risk in Dialysis, Trial Suggests

Dec 13th, 2018 - Alfacalcidol does not reduce the risk for cardiovascular events in patients without secondary hyperparathyroidism undergoing maintenance hemodialysis compared with usual care, the Japan Dialysis Active Vitamin D (J-DAVID) trial has found. But experts question the generalizability of the findings. During a median of 4 years, the composite outcome of select cardiovascular events was 21.1% in thos...

FDA OKs Devices for Parathyroid Tissue Detection During Surgery

Nov 1st, 2018 - The US Food and Drug Administration (FDA) has cleared two devices that provide real-time location of parathyroid tissue during surgical procedures such as thyroidectomy and parathyroidectomy, the agency has announced. One is the Fluobeam 800 Clinic Imaging Device from Fluoptics and the other is the Parathyroid Detection PTeye System from AiBiomed. For surgeons treating hyperparathyroidism or ot...

Primary hyperparathyroidism: Labs to order, Tx to consider
MDedge Family Medicine;

Nov 1st, 2018 - 24-hour urinary Ca2+ A 24-hour urinary Ca2+ excretion is used to assess the risk of renal stones and to differentiate PHPT from familial hypocalciuric hypercalcemia (FHH). Patients with FHH have an abnormality in Ca2+ receptor gene expression in parathyroid cells and renal tubular cells that could lead to parathyroid-mediated hypercalcemia and hypocalciuria.

In reply: Postsurgical hypoparathyroidism is not primary hypoparathyroidism
Sohab S. Radwan, MD, Khair M. Hamo, MD et. al.

Oct 1st, 2018 - In Reply: We thank Dr. Parmar and appreciate his important comments.

Postsurgical hypoparathyroidism is not primary hypoparathyroidism
Malvinder S. Parmar, MB, MS, FRCPC, FACP, FASN

Oct 1st, 2018 - To the Editor: I read with interest the case of a 67-year-old woman with bilateral hand numbness , published in the March 2018 issue of the Journal, and I would like to suggest 2 important corrections to this article. 1 The authors present a case of hypocalcemia secondary to postsurgical hypoparathyroidism but describe it as due to primary hypoparathyroidism.

Optimizing calcium and vitamin D intake through diet and supplements
Holly P. Kilim, MD, Harold Rosen, MD

Jul 2nd, 2018 - Although calcium and vitamin D are often recommended for prevention and treatment of osteoporosis, considerable controversy exists in terms of their safety and efficacy. 1 This article highlights the issues, referring readers to reviews and meta-analyses for details and providing some practical advice for patients requiring supplementation.

Primary hPTH often goes unnoticed
Jim Kling

Jun 4th, 2018 - SAN FRANCISCO – Primary hyperparathyroidism was detected in 7% of 742 patients with recurrent kidney stones at a single tertiary care clinic, and the patients’ primary care physicians may have missed the diagnosis because several affected patients’ calcium levels were in the high normal range. Of the 53 patients diagnosed with primary hyperparathyroidism (hPTH), 72% had high normal serum calciu.

Lab Tests Can Pinpoint Risk of Hypoparathyroidism After Surgery

May 21st, 2018 - BOSTON — Patients with low calcium and parathyroid hormone (PTH) levels immediately following total thyroidectomy, and those with significant drops in those values from baseline, are at highest risk for developing permanent hypoparathyroidism, new research suggests. The findings from a single-center retrospective review of post-thyroidectomy patients were presented May 17 here at the American A...

Calcium, PTH predict permanent hypoparathyroidism

May 18th, 2018 - By comparing the levels before and after a thyroidectomy, physicians can act faster and more accurately when determining how best to treat patients to prevent hypoparathyroidism, a practice which, according to Dr. Brown, has already begun to be put into place.

CKD Linked to Cognitive Impairment in Kids

Feb 22nd, 2018 - Action Points Children with chronic kidney disease (CKD) may have low-average neurocognitive and academic outcomes, and cognition appears to worsen with advancing CKD, with children on dialysis having the poorest performance, according to a systematic literature review. Note that possible reasons for lower cognitive abilities in CKD include the consequences of increased plasma levels of uremic ...

She’s Not My Mother: A 24-Year-Old Man With Capgras Delusion

Dec 22nd, 2017 - Discussion The Capgras delusion can present in several different contexts. A psychiatric differential diagnosis includes disorders in the schizophrenia spectrum (brief psychotic disorder, schizophreniform disorder, and schizophrenia), schizoaffective disorder, delusional disorder, and substance-induced psychotic disorder.